These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 10418915)
1. Intranasal murine model of Bordetella pertussis infection: II. Sequence variation and protection induced by a tricomponent acellular vaccine. Boursaux-Eude C; Thiberge S; Carletti G; Guiso N Vaccine; 1999 Jun; 17(20-21):2651-60. PubMed ID: 10418915 [TBL] [Abstract][Full Text] [Related]
2. Sequence variation in pertussis S1 subunit toxin and pertussis genes in Bordetella pertussis strains used for the whole-cell pertussis vaccine produced in Poland since 1960: efficiency of the DTwP vaccine-induced immunity against currently circulating B. pertussis isolates. Gzyl A; Augustynowicz E; Gniadek G; Rabczenko D; Dulny G; Slusarczyk J Vaccine; 2004 Jun; 22(17-18):2122-8. PubMed ID: 15149768 [TBL] [Abstract][Full Text] [Related]
3. [Evaluation of whole-cell and acellular pertussis vaccines effectiveness in clearance of experimental B. pertussis infection in mice]. Gzyl A; Augustynowicz E; Zawadka M; Rabczenko D; Slusarczyk J Med Dosw Mikrobiol; 2007; 59(2):123-35. PubMed ID: 17929410 [TBL] [Abstract][Full Text] [Related]
4. Antigenic variants in Bordetella pertussis strains isolated from vaccinated and unvaccinated children. Mastrantonio P; Spigaglia P; Oirschot HV; van der Heide HGJ; Heuvelman K; Stefanelli P; Mooi FR Microbiology (Reading); 1999 Aug; 145 ( Pt 8)():2069-2075. PubMed ID: 10463173 [TBL] [Abstract][Full Text] [Related]
5. Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strains. Bottero D; Gaillard ME; Fingermann M; Weltman G; Fernández J; Sisti F; Graieb A; Roberts R; Rico O; Ríos G; Regueira M; Binsztein N; Hozbor D Clin Vaccine Immunol; 2007 Nov; 14(11):1490-8. PubMed ID: 17699837 [TBL] [Abstract][Full Text] [Related]
7. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model. Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and protective efficacy of a newly developed tri-component diphtheria, tetanus, and acellular pertussis vaccine in a murine model. Huh DH; Han SB; Shin HJ; Ahn DH; Choi GS; Kang KR; Kim BR; Kang JH J Microbiol Immunol Infect; 2018 Dec; 51(6):732-739. PubMed ID: 28720318 [TBL] [Abstract][Full Text] [Related]
9. Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis. Ausiello CM; Urbani F; La Sala A; Lande R; Piscitelli A; Cassone A Dev Biol Stand; 1997; 89():315-20. PubMed ID: 9272365 [TBL] [Abstract][Full Text] [Related]
10. Synergic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular pertussis vaccine in the murine intranasal challenge model. Komatsu E; Yamaguchi F; Abe A; Weiss AA; Watanabe M Clin Vaccine Immunol; 2010 May; 17(5):807-12. PubMed ID: 20357056 [TBL] [Abstract][Full Text] [Related]
11. [Application of DNA microcarriers for evaluation of mice splenocytes genes expression after immunization with pertussis vaccines and challenged with different B. pertussis strains]. Gzyl A; Woyciechowska-Oczko M; Jarzab B; Augustynowicz E; Mosiej E; Slusarczyk J Med Dosw Mikrobiol; 2007; 59(2):149-59. PubMed ID: 17929412 [TBL] [Abstract][Full Text] [Related]
13. Pertactin negative Bordetella pertussis demonstrates higher fitness under vaccine selection pressure in a mixed infection model. Safarchi A; Octavia S; Luu LD; Tay CY; Sintchenko V; Wood N; Marshall H; McIntyre P; Lan R Vaccine; 2015 Nov; 33(46):6277-81. PubMed ID: 26432908 [TBL] [Abstract][Full Text] [Related]
14. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Cherry JD; Gornbein J; Heininger U; Stehr K Vaccine; 1998 Dec; 16(20):1901-6. PubMed ID: 9796041 [TBL] [Abstract][Full Text] [Related]
15. Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines. Guiso N; Capiau C; Carletti G; Poolman J; Hauser P Vaccine; 1999 May; 17(19):2366-76. PubMed ID: 10392618 [TBL] [Abstract][Full Text] [Related]
17. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Storsaeter J; Hallander HO; Gustafsson L; Olin P Vaccine; 1998 Dec; 16(20):1907-16. PubMed ID: 9796042 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of experimental and commercial pertussis vaccines in the elimination of Bordetella pertussis isolates with different genetic profiles in murine model. Prygiel M; Mosiej E; Wdowiak K; Górska P; Polak M; Lis K; Krysztopa-Grzybowska K; Zasada AA Med Microbiol Immunol; 2021 Dec; 210(5-6):251-262. PubMed ID: 34338880 [TBL] [Abstract][Full Text] [Related]
19. Bordetella pertussis pertactin knock-out strains reveal immunomodulatory properties of this virulence factor. Hovingh ES; Mariman R; Solans L; Hijdra D; Hamstra HJ; Jongerius I; van Gent M; Mooi F; Locht C; Pinelli E Emerg Microbes Infect; 2018 Mar; 7(1):39. PubMed ID: 29559630 [TBL] [Abstract][Full Text] [Related]
20. Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom. Fry NK; Neal S; Harrison TG; Miller E; Matthews R; George RC Infect Immun; 2001 Sep; 69(9):5520-8. PubMed ID: 11500425 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]